# A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine

> **NCT00013897** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Lamivudine/Zidovudine
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT00013897
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** — (—)
- **Last updated:** 2011-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00013897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00013897, "A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00013897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*